(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 277.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Humacyte's revenue in 2025 is $1,571,000.On average, 9 Wall Street analysts forecast HUMA's revenue for 2025 to be $539,715,947, with the lowest HUMA revenue forecast at $390,835,247, and the highest HUMA revenue forecast at $723,616,384. On average, 9 Wall Street analysts forecast HUMA's revenue for 2026 to be $4,485,335,409, with the lowest HUMA revenue forecast at $2,024,028,437, and the highest HUMA revenue forecast at $8,775,908,645.
In 2027, HUMA is forecast to generate $17,515,861,196 in revenue, with the lowest revenue forecast at $9,176,294,729 and the highest revenue forecast at $30,124,464,696.